Y
Yaxin Chen
Researcher at China Pharmaceutical University
Publications - 5
Citations - 75
Yaxin Chen is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Gene silencing & Downregulation and upregulation. The author has an hindex of 3, co-authored 5 publications receiving 30 citations.
Papers
More filters
Journal ArticleDOI
Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation
Tao Li,Bin Fu,Xin Zhang,Yunjiang Zhou,Mengdi Yang,Mengran Cao,Yaxin Chen,Yingying Tan,Rong Hu +8 more
TL;DR: In this paper, the authors found that 5-HT levels, as well as the expression of tryptophan hydroxylase 1 (TPH1), the 5HT biosynthesis rate-limiting enzyme, were significantly upregulated in colorectal tumor tissues from patients with colortal cancer.
Journal ArticleDOI
HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling.
Yunjiang Zhou,Keke Wang,Yang Zhou,Tao Li,Mengdi Yang,Rui Wang,Yaxin Chen,Mengran Cao,Rong Hu +8 more
TL;DR: It is suggested that HEATR1 deficiency promotes proliferation and gemcitabine resistance of pancreatic cancer through up-regulating Nrf2 signaling, indicating that HEatR1 may be a promising therapeutic target for pancreatic cancers.
Journal ArticleDOI
Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway.
Yunjiang Zhou,Yang Zhou,Keke Wang,Tao Li,Mengdi Yang,Rui Wang,Yaxin Chen,Mengran Cao,Rong Hu +8 more
TL;DR: Flumethasone can potentially be used as an adjuvant sensitizer to enhance the efficacy of chemotherapeutic drugs in lung cancer and is found to inhibited Nrf2 signaling in A549 and H460 cells by promoting NRF2 protein degradation.
Journal ArticleDOI
An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy.
TL;DR: In this article, a potent anticancer D-peptide supramolecular nanomedicine targeting NRP1 and MDM2, termed as NMTP-5, is identified by using structure-based virtual screening techniques.
Journal ArticleDOI
A Supramolecular Nanomedicine Based on Bendamustine and MDM2-Targeted D-peptide Inhibitor for Breast Cancer Therapy.
TL;DR: Wang et al. as discussed by the authors developed a self-assembling D-peptide-small molecule drug conjugate (BEN-FF-PEptide 5) by simultaneously conjugating small molecule drug BEN and peptide 5 to the selfassembling peptide.